The ALS Association has launched a free tool to help ALS patients and their families navigate health insurance denials and ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback